Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A
Identifieur interne : 002A73 ( Istex/Corpus ); précédent : 002A72; suivant : 002A74Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A
Auteurs : Brashear ; Walter T. Ambrosius ; George J. Eckert ; Eric R. SiemersSource :
- Movement Disorders [ 0885-3185 ] ; 1998-01.
English descriptors
- KwdEn :
Abstract
To compare clinical parameters of patients treated with botulinum toxin type A (BTX) for treatment of idiopathic cervical dystonia (ICD) and for tardive cervical dystonia (TCD), we studied 156 patients (149 with ICD and 7 with TCD) who were treated with serial injections of BTX over 5 years. We hypothesized that patients with TCD and ICD would demonstrate similar improvement in severity scores after treatment with BTX. The diagnosis, dates, dosages, and frequency of BTX injected and severity assessments were recorded into a computerized database. Nonparametric Wilcoxon rank sum and signed‐rank tests were used to assess statistical significance. The change in severity scores between the first treatment and last treatment in both groups was not statistically significant (p = 0.4859), indicating similar improvement. The difference in BTX doses was significant (p = 0.0045). ICD patients (n = 149) received an average of 219.8 ± 63.5 units and those with TCD (n = 7) were treated with an average dose of 287.4 ± 60.3 units. The average number of days between treatments for individuals with ICD was 142.9 ± 85.8, similar to that for persons with TCD (144.7 ± 64.5) (p = 0.6075). Our analysis provides preliminary evidence that the improvement from the administration of BTX for patients with ICD and TCD is similar.
Url:
DOI: 10.1002/mds.870130130
Links to Exploration step
ISTEX:2B62EE88EB98EEB1F2972AF810B69B71BCF88701Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A</title><author><name sortKey="Brashear" sort="Brashear" uniqKey="Brashear" last="Brashear">Brashear</name><affiliation><mods:affiliation>Department of Neurology and Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Ambrosius, Walter T" sort="Ambrosius, Walter T" uniqKey="Ambrosius W" first="Walter T." last="Ambrosius">Walter T. Ambrosius</name><affiliation><mods:affiliation>Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Eckert, George J" sort="Eckert, George J" uniqKey="Eckert G" first="George J." last="Eckert">George J. Eckert</name><affiliation><mods:affiliation>Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Siemers, Eric R" sort="Siemers, Eric R" uniqKey="Siemers E" first="Eric R." last="Siemers">Eric R. Siemers</name><affiliation><mods:affiliation>Department of Neurology and Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2B62EE88EB98EEB1F2972AF810B69B71BCF88701</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1002/mds.870130130</idno><idno type="url">https://api.istex.fr/document/2B62EE88EB98EEB1F2972AF810B69B71BCF88701/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002A73</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A</title><author><name sortKey="Brashear" sort="Brashear" uniqKey="Brashear" last="Brashear">Brashear</name><affiliation><mods:affiliation>Department of Neurology and Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Ambrosius, Walter T" sort="Ambrosius, Walter T" uniqKey="Ambrosius W" first="Walter T." last="Ambrosius">Walter T. Ambrosius</name><affiliation><mods:affiliation>Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Eckert, George J" sort="Eckert, George J" uniqKey="Eckert G" first="George J." last="Eckert">George J. Eckert</name><affiliation><mods:affiliation>Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Siemers, Eric R" sort="Siemers, Eric R" uniqKey="Siemers E" first="Eric R." last="Siemers">Eric R. Siemers</name><affiliation><mods:affiliation>Department of Neurology and Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-01">1998-01</date><biblScope unit="vol">13</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="158">158</biblScope><biblScope unit="page" to="161">161</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">2B62EE88EB98EEB1F2972AF810B69B71BCF88701</idno><idno type="DOI">10.1002/mds.870130130</idno><idno type="ArticleID">MDS870130130</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Botulinum toxin</term><term>Tardive dystonia</term><term>Torticollis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To compare clinical parameters of patients treated with botulinum toxin type A (BTX) for treatment of idiopathic cervical dystonia (ICD) and for tardive cervical dystonia (TCD), we studied 156 patients (149 with ICD and 7 with TCD) who were treated with serial injections of BTX over 5 years. We hypothesized that patients with TCD and ICD would demonstrate similar improvement in severity scores after treatment with BTX. The diagnosis, dates, dosages, and frequency of BTX injected and severity assessments were recorded into a computerized database. Nonparametric Wilcoxon rank sum and signed‐rank tests were used to assess statistical significance. The change in severity scores between the first treatment and last treatment in both groups was not statistically significant (p = 0.4859), indicating similar improvement. The difference in BTX doses was significant (p = 0.0045). ICD patients (n = 149) received an average of 219.8 ± 63.5 units and those with TCD (n = 7) were treated with an average dose of 287.4 ± 60.3 units. The average number of days between treatments for individuals with ICD was 142.9 ± 85.8, similar to that for persons with TCD (144.7 ± 64.5) (p = 0.6075). Our analysis provides preliminary evidence that the improvement from the administration of BTX for patients with ICD and TCD is similar.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Dr. Brashear MD</name><affiliations><json:string>Department of Neurology and Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.</json:string></affiliations></json:item><json:item><name>Walter T. Ambrosius PhD</name><affiliations><json:string>Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.</json:string></affiliations></json:item><json:item><name>George J. Eckert MAS</name><affiliations><json:string>Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.</json:string></affiliations></json:item><json:item><name>Eric R. Siemers MD</name><affiliations><json:string>Department of Neurology and Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Tardive dystonia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Torticollis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Botulinum toxin</value></json:item></subject><language><json:string>eng</json:string></language><abstract>To compare clinical parameters of patients treated with botulinum toxin type A (BTX) for treatment of idiopathic cervical dystonia (ICD) and for tardive cervical dystonia (TCD), we studied 156 patients (149 with ICD and 7 with TCD) who were treated with serial injections of BTX over 5 years. We hypothesized that patients with TCD and ICD would demonstrate similar improvement in severity scores after treatment with BTX. The diagnosis, dates, dosages, and frequency of BTX injected and severity assessments were recorded into a computerized database. Nonparametric Wilcoxon rank sum and signed‐rank tests were used to assess statistical significance. The change in severity scores between the first treatment and last treatment in both groups was not statistically significant (p = 0.4859), indicating similar improvement. The difference in BTX doses was significant (p = 0.0045). ICD patients (n = 149) received an average of 219.8 ± 63.5 units and those with TCD (n = 7) were treated with an average dose of 287.4 ± 60.3 units. The average number of days between treatments for individuals with ICD was 142.9 ± 85.8, similar to that for persons with TCD (144.7 ± 64.5) (p = 0.6075). Our analysis provides preliminary evidence that the improvement from the administration of BTX for patients with ICD and TCD is similar.</abstract><qualityIndicators><score>4.73</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1323</abstractCharCount><pdfWordCount>2174</pdfWordCount><pdfCharCount>13038</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>213</abstractWordCount></qualityIndicators><title>Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A</title><genre><json:string>Serial article</json:string></genre><host><volume>13</volume><pages><total>4</total><last>161</last><first>158</first></pages><issn><json:string>0885-3185</json:string></issn><issue>1</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>1998</publicationDate><copyrightDate>1998</copyrightDate><doi><json:string>10.1002/mds.870130130</json:string></doi><id>2B62EE88EB98EEB1F2972AF810B69B71BCF88701</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/2B62EE88EB98EEB1F2972AF810B69B71BCF88701/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/2B62EE88EB98EEB1F2972AF810B69B71BCF88701/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/2B62EE88EB98EEB1F2972AF810B69B71BCF88701/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>1998</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A</title><author><persName><surname>Brashear</surname><roleName type="degree">Dr.</roleName></persName><note type="correspondence"><p>Correspondence: 550 University Boulevard, Room 6620, Indianapolis, IN 46202‐5250, U.S.A</p></note><affiliation>Department of Neurology and Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.</affiliation></author><author><persName><forename type="first">Walter T.</forename><surname>Ambrosius</surname><roleName type="degree">PhD</roleName></persName><affiliation>Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.</affiliation></author><author><persName><forename type="first">George J.</forename><surname>Eckert</surname><roleName type="degree">MAS</roleName></persName><affiliation>Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.</affiliation></author><author><persName><forename type="first">Eric R.</forename><surname>Siemers</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology and Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-01"></date><biblScope unit="vol">13</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="158">158</biblScope><biblScope unit="page" to="161">161</biblScope></imprint></monogr><idno type="istex">2B62EE88EB98EEB1F2972AF810B69B71BCF88701</idno><idno type="DOI">10.1002/mds.870130130</idno><idno type="ArticleID">MDS870130130</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1998</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>To compare clinical parameters of patients treated with botulinum toxin type A (BTX) for treatment of idiopathic cervical dystonia (ICD) and for tardive cervical dystonia (TCD), we studied 156 patients (149 with ICD and 7 with TCD) who were treated with serial injections of BTX over 5 years. We hypothesized that patients with TCD and ICD would demonstrate similar improvement in severity scores after treatment with BTX. The diagnosis, dates, dosages, and frequency of BTX injected and severity assessments were recorded into a computerized database. Nonparametric Wilcoxon rank sum and signed‐rank tests were used to assess statistical significance. The change in severity scores between the first treatment and last treatment in both groups was not statistically significant (p = 0.4859), indicating similar improvement. The difference in BTX doses was significant (p = 0.0045). ICD patients (n = 149) received an average of 219.8 ± 63.5 units and those with TCD (n = 7) were treated with an average dose of 287.4 ± 60.3 units. The average number of days between treatments for individuals with ICD was 142.9 ± 85.8, similar to that for persons with TCD (144.7 ± 64.5) (p = 0.6075). Our analysis provides preliminary evidence that the improvement from the administration of BTX for patients with ICD and TCD is similar.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Tardive dystonia</term></item><item><term>Torticollis</term></item><item><term>Botulinum toxin</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1997-04-07">Received</change><change when="1997-07-18">Registration</change><change when="1998-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/2B62EE88EB98EEB1F2972AF810B69B71BCF88701/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="tocForm">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="10"><doi origin="wiley" registered="yes">10.1002/mds.v13:1</doi><numberingGroup><numbering type="journalVolume" number="13">13</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="1998-01">January 1998</coverDate></publicationMeta><publicationMeta level="unit" type="shortCommunication" position="30" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.870130130</doi><idGroup><id type="unit" value="MDS870130130"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 1998 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="1997-04-07"></event><event type="manuscriptRevised" date="1997-07-17"></event><event type="manuscriptAccepted" date="1997-07-18"></event><event type="firstOnline" date="2004-11-04"></event><event type="publishedOnlineFinalForm" date="2004-11-04"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">158</numbering><numbering type="pageLast">161</numbering></numberingGroup><correspondenceTo>550 University Boulevard, Room 6620, Indianapolis, IN 46202‐5250, U.S.A</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS870130130.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="12"></count></countGroup><titleGroup><title type="main" xml:lang="en">Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A</title><title type="short" xml:lang="en">BOTULINUM TOXIN FOR TARDIVE DYSTONIA</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><honorifics>Dr.</honorifics><givenNames>Allison</givenNames><familyName>Brashear</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Walter T.</givenNames><familyName>Ambrosius</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>George J.</givenNames><familyName>Eckert</familyName><degrees>MAS</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Eric R.</givenNames><familyName>Siemers</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology and Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Tardive dystonia</keyword><keyword xml:id="kwd2">Torticollis</keyword><keyword xml:id="kwd3">Botulinum toxin</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>To compare clinical parameters of patients treated with botulinum toxin type A (BTX) for treatment of idiopathic cervical dystonia (ICD) and for tardive cervical dystonia (TCD), we studied 156 patients (149 with ICD and 7 with TCD) who were treated with serial injections of BTX over 5 years. We hypothesized that patients with TCD and ICD would demonstrate similar improvement in severity scores after treatment with BTX. The diagnosis, dates, dosages, and frequency of BTX injected and severity assessments were recorded into a computerized database. Nonparametric Wilcoxon rank sum and signed‐rank tests were used to assess statistical significance. The change in severity scores between the first treatment and last treatment in both groups was not statistically significant (p = 0.4859), indicating similar improvement. The difference in BTX doses was significant (p = 0.0045). ICD patients (n = 149) received an average of 219.8 ± 63.5 units and those with TCD (n = 7) were treated with an average dose of 287.4 ± 60.3 units. The average number of days between treatments for individuals with ICD was 142.9 ± 85.8, similar to that for persons with TCD (144.7 ± 64.5) (p = 0.6075). Our analysis provides preliminary evidence that the improvement from the administration of BTX for patients with ICD and TCD is similar.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>BOTULINUM TOXIN FOR TARDIVE DYSTONIA</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A</title></titleInfo><name type="personal"><namePart type="termsOfAddress">Dr.</namePart><namePart type="family">Brashear</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology and Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.</affiliation><description>Correspondence: 550 University Boulevard, Room 6620, Indianapolis, IN 46202‐5250, U.S.A</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Walter T.</namePart><namePart type="family">Ambrosius</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">George J.</namePart><namePart type="family">Eckert</namePart><namePart type="termsOfAddress">MAS</namePart><affiliation>Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Eric R.</namePart><namePart type="family">Siemers</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology and Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">shortCommunication</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1998-01</dateIssued><dateCaptured encoding="w3cdtf">1997-04-07</dateCaptured><dateValid encoding="w3cdtf">1997-07-18</dateValid><copyrightDate encoding="w3cdtf">1998</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">1</extent><extent unit="references">12</extent></physicalDescription><abstract lang="en">To compare clinical parameters of patients treated with botulinum toxin type A (BTX) for treatment of idiopathic cervical dystonia (ICD) and for tardive cervical dystonia (TCD), we studied 156 patients (149 with ICD and 7 with TCD) who were treated with serial injections of BTX over 5 years. We hypothesized that patients with TCD and ICD would demonstrate similar improvement in severity scores after treatment with BTX. The diagnosis, dates, dosages, and frequency of BTX injected and severity assessments were recorded into a computerized database. Nonparametric Wilcoxon rank sum and signed‐rank tests were used to assess statistical significance. The change in severity scores between the first treatment and last treatment in both groups was not statistically significant (p = 0.4859), indicating similar improvement. The difference in BTX doses was significant (p = 0.0045). ICD patients (n = 149) received an average of 219.8 ± 63.5 units and those with TCD (n = 7) were treated with an average dose of 287.4 ± 60.3 units. The average number of days between treatments for individuals with ICD was 142.9 ± 85.8, similar to that for persons with TCD (144.7 ± 64.5) (p = 0.6075). Our analysis provides preliminary evidence that the improvement from the administration of BTX for patients with ICD and TCD is similar.</abstract><subject lang="en"><genre>Keywords</genre><topic>Tardive dystonia</topic><topic>Torticollis</topic><topic>Botulinum toxin</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>158</start><end>161</end><total>4</total></extent></part></relatedItem><identifier type="istex">2B62EE88EB98EEB1F2972AF810B69B71BCF88701</identifier><identifier type="DOI">10.1002/mds.870130130</identifier><identifier type="ArticleID">MDS870130130</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1998 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A73 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002A73 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:2B62EE88EB98EEB1F2972AF810B69B71BCF88701
|texte= Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A
}}
| This area was generated with Dilib version V0.6.23. |  |